•The U.S. and Israel have initiated major combat operations and a broad military campaign against targets across Iran.
•A Bloomberg strategist warned that Trump's rhetoric urging regime change could lead to a prolonged era of high volatility rather than a one-off shock.
•Unusual options market activity, including SPY puts and gold/silver calls, was observed prior to the strikes.
•China has approved Jaypirca (pirtobrutinib) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
•Innovent Biologics (HKEX: 01801) is the partner involved in the development and commercialization of the drug in China.
•SEP-631 demonstrated robust, dose-dependent inhibition of skin wheal formation, with complete inhibition observed at doses as low as 10 mg once-daily.
•The drug was well-tolerated across all doses studied with an adverse event profile comparable to placebo.
•Phase 2 development for Chronic Spontaneous Urticaria (CSU) is planned to begin in the second half of 2026.
